ALA and ALA hexyl ester induction of porphyrins after their systemic administration to tumour bearing mice

British Journal of Cancer

Volumn 87, Issue 7, 2002, Pages 790-795

  Perotti, C ^a   Casas, A ^a   Fukuda, H ^a   Sacca, P ^a   Batlle, A ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

ALA derivatives; ALA hexyl ester; Aminolevulinic acid, ALA; Blood brain barrier; Photodynamic therapy, PDT

Indexed keywords

AMINOLEVULINIC ACID; PORPHYRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; BLOOD BRAIN BARRIER; BRAIN TUMOR; DRUG EFFECT; MALE; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; TUMOR;

AMINOLEVULINIC ACID; ANIMALS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; ORGAN SPECIFICITY; PORPHYRINS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0037163735     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600559     Document Type: Article

References (32)

1. Berger Y, Greppi A, Siri O, Neier R, Jullierat-Jeanneret L (2000) Ethylene glycol and amino acid derivatives of 5-aminolevulinic acid as new photo-sensitizing precursors of Protoporphyrin IX. J Med Chem 43: 4738-4746
2. Bermúdez Moretti M, Correa García S, Perotti C, Batlle A, Casas A (2002) δ-aminolevulinic acid transport in mammary adenocarcinoma cells is mediated by beta transporters. Br J Cancer (in press)
3. Casas A, Batlle A, Butler A, Robertson D, Brown E, MacRobert A, Riley P (1999) Comparative effect of ALA derivatives on Protoporphyrin IX production in human and rat skin organ cultures. Br J Cancer 80: 1525-1532
4. Casas A, Fukuda H, Di Venosa G, Batlle A (2001a) Photosensitisation and mechanism of cytotoxicity induced by the use of ALA derivatives in photo-dynamic therapy. Br J Cancer 85: 279-284
5. Casas A, Perotti C, Fukuda H, Rogers L, Butler A, Batlle A (2001b) Hexyl-ALA induces selective porphyrin synthesis in chemically induced skin tumours confined to the site of application: implications in cutaneous photosensitisation. Br J Cancer 85: 1740-1800
6. Casas A, Batlle A (2002) Rational design of 5-aminolevulinic acid derivatives aimed at improving Photodynamic Therapy. Curr Med Chem Anti-Cancer Agents 2: 465-475
7. Endlicher E, Rümmele P, Hausmann F, Krief R, Knüchel R, Rath HC, Schölmerich H, Messmann H (2001) Protoporphyrin IX distribution following local application of 5-aminolevulinic acid and its esterified derivatives in the tissue layers of the normal rat colon. Br J Cancer 85: 1572-1576
8. Fukuda H, Paredes S, Batlle A (1989) Tumor-localizing properties of porphyrins. in vitro studies using the porphyrin precursor, aminoevulinic acid, in free and liposome encapsulated forms. Drug Des Deliv 6: 133-139
9. Fukuda H, Paredes S, Batlle A (1992) Tumour-localizing properties of porphyrins. in vivo studies using free and liposome encapsulated aminole-vulinic acid. Comp Biochem Physiol 102B: 433-436
10. Galli S, Colombo L, Vanzuli S, Daroqui M, Vidal M, Jasnis A, Lustig E, Eiján A (2000) Characterization of a fibroblastoid mammary carcinoma cell line (LM2) originated from a mouse adenocarcinoma. Int J Oncol 17: 1259-1265
11. Gaullier J, Berg K, Peng Q, Anholt H, Selbo P, Ma L, Moan J (1997) Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture. Cancer Res 57: 1481-1486
12. Gil M, Woszczynski M, Regula J, MacRobert A, Butruk E, Bown S (1999) Topical versus systemic 5-aminolevulinic acid administration for photodynamic therapy of the colon in B10.RBP mice. J Biomedical Optics 4: 286-201
13. Gloor S, Wachtel M, Bolliger M, Ishihara H, Landmann R, Frei K (2001) Molecular and cellular permeability control at the blood-brain barrier. Brain Res Rev 36: 258-264
14. Gorchein A, Webber R (1987) 5-aminolevulinic acid in plasma, cerebrospinal fluid, saliva and erythrocytes: studies in normal, uraemic and porphyric subjects. Clin Sci 72: 103-112
15. Hansch C, Bjorkroth J, Leo A (1987) Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. J Pharm Sci 76: 663-687
16. Kennedy J, Pottier R, Pross D (1990) Photodynamic therapy with endogenous protoporphyrin IX: basic principles and basic clinical experience. J Photochem Photobiol B: Biol 6: 143-148
17. Kloek J, Akkermans W, Beijersbergen van Henegouwen G (1998) Derivatives of 5-Aminolevulinic acid for Photodynamic therapy: enzymatic conversion into protoporphyrin. Photochem Photobiol 67: 150-154
18. Kloek J, Beijersbergen van Henegouwen G (1996) Prodrugs of 5-aminolevulinic acid for photodynamic therapy. Photochem Photobiol 64: 994-1000
19. Kriegmair M, Baumgartner R, Knuechel R, Stepp H, Hofstädter F, Hofstetter A (1996) Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urology 155: 105-110
20. Krogsgaard-Larsen P, Frolund B, Frydenvang K (2000) GABA uptake inhibitors, design, molecular pharmacology and therapeutic aspects. Curr Pharm Design 6: 1193-1209
21. Lange N, Jichinlinski P, Zellweger M, Forrer M, Marti A, Guillou L, Kuchera P, Wagnieres G, van den Bergh H (1999) Photodetection of early human bladder cancer based on the fluorescence of 5-aminolevulinic acid hexylester-induced protoporhyrin IX: a pilot study. Br J Cancer 80: 185-193
22. Loh C, MacRobert A, Bedwell J, Krasner N, Bown S (1993) Oral versus intravenous administration of 5-aminolevulinic acid for photodynamic therapy. Br J Cancer 68: 41-51
23. Luksiene Z, Eggen I, Moan J, Nesland JM, Peng Q (2001) Evaluation of protoporphyrin IX production, phototoxicity and cell death pathway induced by hexylester of 5-aminolevulinic acid in Reh and HPB-ALL cells. Cancer Letters 169: 33-39
24. Marti A, Lange N, van den Bergh H, Sedmera D, Jichlinski P, Kucera P (1999) Optimisation of the formation and distribution of protoporphyrin IX in the urothelium: an in vitro approach. J Urol 162: 546-552
25. Mauzerall D, Granick S (1956) The occurrence and determination of 5-aminolevulinic acid and porphobilinogen in urine. J Biol Chem 219: 435-446
26. Moan J, Ma L, Iani V (2001) On the pharmacokinetics of topically applied 5-aminolevulinic acid and two of its esters. Int J Cancer 92: 139-143
27. Percy V, Shanley B (1979) Studies on haem biosynthesis in rat brain. J Neurochem 33: 1267-1274
28. Polo C, Navone N, Afonso S, Vazquez E, Buzaleh A, Bianchi A, Schoua E, Batlle A (1988) Induction of porphyrin biosynthesis in tissue explants and the effect of anitimitotics. ATLA 16: 137-147
29. Sweeney V, Pathak M, Asbury A (1970) Acute intermittent porphyria, increased ALA-synthetase activity during an acute attack. Brain 93: 369-380
30. Uehlinger P, Zellweger M, Wagnieres G, Juillerat-Jeanneret L, van den Bergh H, Lange N (2000) 5-aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells. J Photochem Photobiol B:Biol 54: 72-80
31. UK-Coordinating Committee on Cancer Research (1988) UKCCCR Guidelines for the Welfare of Animals in Experimental Neoplasia. London: UKCCCR
32. van den Akker J, Iani V, Star W, Sterenborg H, Moan JV (2000) Topical application of 5-aminolevulinic acid hexyl ester and 5-aminolevulinic to normal nude mouse skin: differences in Protoporphyrin IX fluorescence kinetics and the role of the stratum corneum. Photochem Photobiol 72: 681-689